MEDI0457

DRUG2 trials

Sponsors

MedImmune LLC, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

HPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related CarcinomaHead and Neck CancerHuman Papilloma VirusOropharynx Cancer

Phase 1

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

CompletedNCT03162224

MedImmune LLCHead and Neck Cancer, Human Papilloma Virus

Start: 2017-06-26End: 2021-03-19Updated: 2022-08-25

Phase 2

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

WithdrawnNCT04001413

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsHPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma, Oropharynx Cancer

Start: 2019-09-17End: 2021-03-25Updated: 2022-07-29

Related Papers

A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.

Journal of Clinical Oncology2018-05-206 citations